Yes, @kmsmith addressed this in the fourth point in his first...

Yes, @kmsmith addressed this in the fourth point in his first post. It is expected that recruitment will be accelerated, especially in the KEYNOTE study once the safety is proven in the early cohorts, as required by the FDA. In the other studies, the impressive ongoing results will encourage oncologists to offer up Cavatak as one of the options to try, especially with those patients that have failed other treatments.

As an aside, I went to the AGM for the first time to meet the directors to make sure they are the real deal, especially as I have a lot invested in VLA. It was well worth it even though I didn't learn a lot more. I'm much more motivated (my patience had been wearing thin until today) and await further positive results next year.

GLTAH
.